Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
The Lancet. Global Health|July 25, 2025
Regional and type-specific variations in the global seasonality of human parainfluenza viruses and the influence of climatic factors: a systematic review and meta-analysisJunru Chen, Shuyu Deng, Xiaoyu Xu, et al.
The Prostate|August 22, 2019
Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?Tao Wu, Jinge Zhao, Zhenhua Liu, et al.
Microbiome|February 2, 2017
Gut microbiota dysbiosis contributes to the development of hypertensionJing Li, Fangqing Zhao, Yidan Wang, et al.
Discover Oncology|November 4, 2025
CircPPP1CB subtype, hsa_circ_0007439, promotes nasopharyngeal carcinoma progression by upregulating KRT1Fei Li, Ting Xu, Rui Sun, et al.
The Prostate|April 17, 2024
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67Fengnian Zhao, Jinge Zhao, Xinyuan Wei, et al.
Clinical Epigenetics|August 8, 2022
Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinomaJunjie Zhao, Jiayu Liang, Yang Yang, et al.
BJU International|May 18, 2018
Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancerJinge Zhao, Guangxi Sun, Banghua Liao, et al.
The Prostate|May 24, 2021
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patientsSha Zhu, Junru Chen, Yuchao Ni, et al.
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Pageof 20